Simon Garinet
Overview
Explore the profile of Simon Garinet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sullo F, Garinet S, Blons H, Taieb J, Laurent-Puig P, Gallois C
Crit Rev Oncol Hematol
. 2025 Feb;
208:104656.
PMID: 39922396
Colorectal cancer (CRC) is the third leading cause of cancer death and accounts for 10 % of cancer diagnoses worldwide. Despite the advancements achieved over the latest decades, CRC treatments...
2.
Lailler C, Didelot A, Garinet S, Berthou H, Sroussi M, De Reynies A, et al.
Oncogene
. 2024 Aug;
43(37):2781-2794.
PMID: 39147880
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib,...
3.
El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, et al.
Cell Rep
. 2024 Jun;
43(6):114350.
PMID: 38870013
Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers to improving outcomes for sRCC are...
4.
Garinet S, Lupo A, Denize T, Loyaux R, Timsit S, Gazeau B, et al.
Pathology
. 2024 Jun;
56(5):702-709.
PMID: 38834439
Metastatic non-small-cell lung cancer (NSCLC) displays various molecular alterations in the RAS-MAPK pathway. In particular, NSCLCs show high rates of targetable gene fusion in ALK, RET, ROS1, NRG1 and NTRK,...
5.
Azais H, Garinet S, Benoit L, de Jesus J, Zizi M, Landman S, et al.
J Gynecol Obstet Hum Reprod
. 2024 May;
53(7):102796.
PMID: 38729429
Objective: BRCA1 promoter methylation (BRCA1pm) is suspected to alter prognosis of patients with epithelial ovarian cancer (EOC). We aimed to evaluate the prognostic impact of this epigenetic modification. Methods: We...
6.
Oudart J, Garinet S, Leger C, Barlesi F, Mazieres J, Jeannin G, et al.
Lung Cancer
. 2024 Mar;
190:107508.
PMID: 38428265
Background: STK11/LKB1 mutations have been associated with primary resistance to PD-1 axis inhibitors and poor prognosis in advanced KRAS-mutant lung adenocarcinoma. This study aimed to assess the prognostic significance of...
7.
Konda P, Garinet S, Van Allen E, Viswanathan S
Cell Rep
. 2023 Aug;
42(8):112978.
PMID: 37572322
The success of precision oncology-which aims to match the right therapies to the right patients based on molecular status-is predicated on a robust pipeline of molecular targets against which therapies...
8.
Garinet S, Didelot A, Marisa L, Beinse G, Sroussi M, Le Pimpec-Barthes F, et al.
J Transl Med
. 2023 May;
21(1):324.
PMID: 37189151
Background: In Lung adenocarcinoma (LUAD), targeted therapies and immunotherapies have moved from metastatic to early stage and stratification of the relapse risk becomes mandatory. Here we identified a miR-200 based...
9.
Garinet S, Rahshenas M, Galmiche-Rolland L, Abbo O, Bonnard A, Hameury F, et al.
Am J Respir Crit Care Med
. 2022 Oct;
207(5):615-619.
PMID: 36288557
No abstract available.
10.
Beinse G, Just P, LE Frere Belda M, Laurent-Puig P, Jacques S, Koual M, et al.
Br J Cancer
. 2022 Jun;
127(6):1123-1132.
PMID: 35752712
Background: Molecular alterations leading to homologous recombination deficiency (HRD) are heterogeneous. We aimed to identify a transcriptional profile shared by endometrial (UCEC), breast (BRCA) and ovarian (OV) cancers with HRD....